# Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

> **NCT02091310** · PHASE1 · COMPLETED · sponsor: **Genfit** · enrollment: 200 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Placebo
- **DRUG:** GFT505
- **DRUG:** Moxifloxacin 400 mg

## Key facts

- **NCT ID:** NCT02091310
- **Lead sponsor:** Genfit
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-12
- **Final completion:** 2015-02
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2015-03-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091310, "Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02091310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*